Date Time
Anticancer drug may improve outcome for severe COVID-19 patients
Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020. On average, blood oxygen levels, body temperature and inflammatory markers significantly improved in patients treated with a single dose of bevacizumab in addition to standard care. The research is published in Nature Communications.
Yihai Cao, photo: Ulf Sirborn
“To reduce COVID-19 mortality, we aim to develop an effective therapeutic paradigm for treating patients with severe COVID-19,” says corresponding author Yihai Cao, professor of vascular biology at the Department of Microbiology, Tumor and Cell Biology at Karolinska Institutet. “Our findings suggest that bevacizumab plus standard care is highly beneficial for patients with severe
E-Mail
IMAGE: AIEgen-based fluorescence detecting system for analysis of TERT mRNA and telomerase activity in different phases of cell cycle (G0/G1, G1/S, S and G2/M phase). view more
Credit: @Science China Press
Cancer is a significant cause of death worldwide and many efforts have been devoted to the development of methods for early detection. Telomerase are considered as a tumor biomarker for early diagnosis because the telomerase of more than 80% immortalized cells are reactivated and provides the sustained proliferative capacity of these cells, but the telomerase activity are not detectable in normal somatic cells. Telomerase is a ribonucleoprotein complex that is thought to add telomeric repeats onto the ends of chromosomes during the replicative phase (S phase) of the cell cycle.
E-Mail
Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer. By using the virus in combination with other drugs, the treatment significantly extended survival in preclinical models of pancreatic cancer.
Viruses that can selectively infect and destroy cancer cells, known as oncolytic viruses, are a promising new class of therapeutics for cancer. Through various mechanisms, oncolytic viruses kill cancer cells and elicit strong anti-tumour immune responses. However, current oncolytic virotherapy is unable to produce a long-term cure in patients, and the treatment has to be delivered directly into the tumour - a route that is not feasible for deeply embedded tumours, or tumours that have spread around the body.
Novel platform uses modified virus to combat pancreatic cancer
Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer.
By using the virus in combination with other drugs, the treatment significantly extended survival in preclinical models of pancreatic cancer.
Viruses that can selectively infect and destroy cancer cells, known as oncolytic viruses, are a promising new class of therapeutics for cancer. Through various mechanisms, oncolytic viruses kill cancer cells and elicit strong anti-tumour immune responses.
However, current oncolytic virotherapy is unable to produce a long-term cure in patients, and the treatment has to be delivered directly into the tumour - a route that is not feasible for deeply embedded tumours, or tumours that have spread around the body.
Scientists Develop Z-scheme Catalyst For Contaminants In Water
In recent years, rapid industrialization has caused increasingly severe environmental pollution. Antibiotics and microbiological contamination in water have become major threats to human health and critical risks to ecosystem security worldwide. Therefore, an effective treatment approach has become an urgent task for elimination of bacterial and antibiotic contamination from the watery environment at present.
Recently, a team led by Prof. WU Zhengyan from the Institute of Intelligent Machines of the Hefei Institutes of Physical Science developed a novel Z-scheme photocatalyst to deal with contaminants in water.
In a study published in the journal